TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 55,150,158 shares, a decline of 2.8% from the November 15th total of 56,767,410 shares. Based on an average daily volume of 2,829,777 shares, the short-interest ratio is presently 19.5 days. Approximately 31.7% of the company’s shares are short sold.

Shares of TherapeuticsMD (NASDAQ TXMD) opened at $6.69 on Thursday. TherapeuticsMD has a twelve month low of $3.50 and a twelve month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The company’s revenue was down 19.7% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS. sell-side analysts expect that TherapeuticsMD will post -0.37 EPS for the current year.

Several equities analysts have recently weighed in on the company. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 17th. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Tuesday. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 target price on the stock. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Thursday, November 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a report on Monday, August 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $15.00.

In other news, Director Tommy G. Thompson acquired 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 23.92% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in TherapeuticsMD by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock worth $136,894,000 after purchasing an additional 2,985,846 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in TherapeuticsMD by 40.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after purchasing an additional 6,340,346 shares during the last quarter. Vanguard Group Inc. increased its holdings in TherapeuticsMD by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after purchasing an additional 429,211 shares during the last quarter. State Street Corp increased its holdings in TherapeuticsMD by 14.9% during the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after purchasing an additional 583,094 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in TherapeuticsMD by 33.4% during the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after purchasing an additional 741,588 shares during the last quarter. Institutional investors own 73.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/14/short-interest-in-therapeuticsmd-inc-txmd-decreases-by-2-8.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.